Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00151203
Recruitment Status : Active, not recruiting
First Posted : September 8, 2005
Last Update Posted : June 4, 2018
Celgene Corporation
Information provided by (Responsible Party):
Weill Medical College of Cornell University